Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1004
- Registration Number
- NCT02928406
- Locations
- 🇪🇪
North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia
🇨🇭Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie, Geneve, Switzerland
🇨🇭Luzerner Kantonsspital; Medizinische Onkologie, Luzern, Switzerland
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02924883
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT02921269
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 700
- Registration Number
- NCT02912559
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Contra Costa Regional Medical Center, Martinez, California, United States
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 514
- Registration Number
- NCT02908672
- Locations
- 🇺🇸
St. Luke's University Health network, Bethlehem, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
🇩🇪Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 186
- Registration Number
- NCT02902029
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Thuringia, Germany
🇩🇪Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, Germany
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02892318
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 67
- Registration Number
- NCT02883062
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
ACTolog in Patients With Solid Cancers
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02876510
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT02876224
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.